Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compoun… Read more
Kintor Pharmaceutical Limited (KNTPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.161x
Based on the latest financial reports, Kintor Pharmaceutical Limited (KNTPF) has a cash flow conversion efficiency ratio of -0.161x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.76 Million) by net assets ($216.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kintor Pharmaceutical Limited - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Kintor Pharmaceutical Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kintor Pharmaceutical Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kintor Pharmaceutical Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crimson Wine
OTCQB:CWGL
|
0.013x |
|
President Bakery Public Company Limited
BK:PB
|
0.029x |
|
Shelf Drilling Ltd
PINK:SHLLF
|
0.039x |
|
COWINTECH Co. Ltd
KQ:282880
|
-0.074x |
|
Arbor Technology
TWO:3594
|
-0.017x |
|
Genovate Biotechnology Co Ltd
TWO:4130
|
0.012x |
|
Aminex PLC
PINK:AEXFF
|
-0.033x |
|
IOL Chemicals and Pharmaceuticals Limited
NSE:IOLCP
|
0.006x |
Annual Cash Flow Conversion Efficiency for Kintor Pharmaceutical Limited (2014–2024)
The table below shows the annual cash flow conversion efficiency of Kintor Pharmaceutical Limited from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $294.08 Million | $-199.08 Million | -0.677x | +19.99% |
| 2023-12-31 | $458.11 Million | $-387.58 Million | -0.846x | -131496.93% |
| 2022-12-31 | $1.50 Billion | $-961.26K | -0.001x | -1.21% |
| 2021-12-31 | $1.66 Billion | $-1.05 Million | -0.001x | -151.48% |
| 2020-12-31 | $1.51 Billion | $-380.88K | 0.000x | +99.96% |
| 2019-12-31 | $369.66K | $-228.04K | -0.617x | -35.16% |
| 2018-12-31 | $251.68K | $-114.87K | -0.456x | -3585.79% |
| 2017-12-31 | $3.63 Million | $-44.96K | -0.012x | -1338.29% |
| 2016-12-31 | $16.85 Million | $-14.51K | -0.001x | -163.50% |
| 2015-12-31 | $39.73 Million | $-12.98K | 0.000x | +46.36% |
| 2014-12-31 | $13.05 Million | $-7.95K | -0.001x | -- |